After treatment with SHP, serum phenylalanine levels significantly decreased, indicating that SHP may alleviate the inhibition by phenylalanine of energy intake, regulate energy metabolism, and then alleviate intestinal motility disorders by regulating the metabolic disorders caused by phenylalanine. The gene discussed is NR0B2; the disease is intestinal motility disease.